PRESIDENT HAS SERVED AS A REVIEWER FOR THE BST-F (80) BIOENGINEERING ‘ACADEMIC RESEARCH ENHANCEMENT AWARD’ STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on March 9, 2017.

pdx news

  • PDX pharma awarded SBIR grant from the National Cancer Institute (total of $2.4M) for the development of PETTRA, a novel lung cancer treatment

    7/6/2023
    read more

  • CEO of PDX Pharma selected as a semi-finalists at the AIM-HI Women’s Venture Competition in Oncology

    5/3/2023
    read more

  • PDX Pharma awarded two-year $1.87M phase II SBIR grant from the National Cancer Institute (NCI) for the development of ARAC-02, a novel lung cancer treatment

    2/21/2023
    read more

Copyright © 2017 PDX Pharmaceuticals, Inc. All rights reserved